Skip to content 
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York. more
| Time Frame | REGN | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 1.69% | 0.91% | -0.82% |
| 1-Month Return | 7.96% | 1.46% | 1.28% |
| 3-Month Return | 9.21% | 3.33% | 3.98% |
| 6-Month Return | 38.03% | 16.03% | 6.73% |
| 1-Year Return | 16.49% | 9.1% | 12.24% |
| 3-Year Return | 6.11% | 21.02% | 72.07% |
| 5-Year Return | 66.06% | 36.15% | 75.69% |
| 10-Year Return | 104.53% | 138.89% | 258.38% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 16.07B | 12.17B | 13.12B | 14.20B | 14.34B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":75.74,"profit":true},{"date":"2023-12-31","value":81.62,"profit":true},{"date":"2024-12-31","value":88.37,"profit":true},{"date":"2025-12-31","value":89.24,"profit":true}] |
| Cost of Revenue | 2.72B | 1.71B | 883.70M | 1.97B | 2.10B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":62.61,"profit":true},{"date":"2023-12-31","value":32.44,"profit":true},{"date":"2024-12-31","value":72.35,"profit":true},{"date":"2025-12-31","value":77.13,"profit":true}] |
| Gross Profit | 13.35B | 10.47B | 12.23B | 12.23B | 12.24B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":78.42,"profit":true},{"date":"2023-12-31","value":91.65,"profit":true},{"date":"2024-12-31","value":91.64,"profit":true},{"date":"2025-12-31","value":91.72,"profit":true}] |
| Gross Margin | 83.05% | 85.99% | 93.26% | 86.13% | 85.35% | [{"date":"2021-12-31","value":89.05,"profit":true},{"date":"2022-12-31","value":92.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":92.35,"profit":true},{"date":"2025-12-31","value":91.52,"profit":true}] |
| Operating Expenses | 4.40B | 5.08B | 7.07B | 8.24B | 8.66B | [{"date":"2021-12-31","value":50.8,"profit":true},{"date":"2022-12-31","value":58.66,"profit":true},{"date":"2023-12-31","value":81.6,"profit":true},{"date":"2024-12-31","value":95.11,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Income | 8.95B | 5.39B | 4.05B | 3.99B | 3.58B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":60.2,"profit":true},{"date":"2023-12-31","value":45.24,"profit":true},{"date":"2024-12-31","value":44.6,"profit":true},{"date":"2025-12-31","value":39.99,"profit":true}] |
| Total Non-Operating Income/Expense | 321.70M | (426.10M) | 497.80M | 1.45B | 2.33B | [{"date":"2021-12-31","value":13.83,"profit":true},{"date":"2022-12-31","value":-18.32,"profit":false},{"date":"2023-12-31","value":21.4,"profit":true},{"date":"2024-12-31","value":62.15,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Pre-Tax Income | 9.33B | 4.86B | 4.20B | 4.78B | 5.23B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":52.1,"profit":true},{"date":"2023-12-31","value":45.03,"profit":true},{"date":"2024-12-31","value":51.25,"profit":true},{"date":"2025-12-31","value":56.09,"profit":true}] |
| Income Taxes | 1.25B | 520.40M | 245.70M | 367.30M | 725.80M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":41.62,"profit":true},{"date":"2023-12-31","value":19.65,"profit":true},{"date":"2024-12-31","value":29.37,"profit":true},{"date":"2025-12-31","value":58.04,"profit":true}] |
| Income After Taxes | 8.08B | 4.34B | 3.95B | 4.41B | 4.50B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.72,"profit":true},{"date":"2023-12-31","value":48.96,"profit":true},{"date":"2024-12-31","value":54.64,"profit":true},{"date":"2025-12-31","value":55.79,"profit":true}] |
| Income From Continuous Operations | 8.08B | 4.34B | 3.99B | 4.41B | 4.50B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.72,"profit":true},{"date":"2023-12-31","value":49.42,"profit":true},{"date":"2024-12-31","value":54.64,"profit":true},{"date":"2025-12-31","value":55.79,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 8.08B | 4.34B | 3.95B | 4.41B | 4.50B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.72,"profit":true},{"date":"2023-12-31","value":48.96,"profit":true},{"date":"2024-12-31","value":54.64,"profit":true},{"date":"2025-12-31","value":55.79,"profit":true}] |
| EPS (Diluted) | 71.38 | 42.40 | 43.78 | 45.64 | 44.38 | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.4,"profit":true},{"date":"2023-12-31","value":61.33,"profit":true},{"date":"2024-12-31","value":63.94,"profit":true},{"date":"2025-12-31","value":62.17,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| REGN | |
|---|---|
| Cash Ratio | 1.97 |
| Current Ratio | 4.13 |
| Quick Ratio | 3.39 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| REGN | |
|---|---|
| ROA (LTM) | 5.91% |
| ROE (LTM) | 14.86% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| REGN | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.23 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.77 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| REGN | |
|---|---|
| Trailing PE | 19.12 |
| Forward PE | 18.25 |
| P/S (TTM) | 5.85 |
| P/B | 2.72 |
| Price/FCF | 91 |
| EV/R | 5.51 |
| EV/Ebitda | 13.58 |
| PEG | 1.53 |
Regeneron Pharmaceuticals Inc (REGN) share price today is $780.6
Yes, Indians can buy shares of Regeneron Pharmaceuticals Inc (REGN) on Vested. To buy
Yes, you can purchase fractional shares of Regeneron Pharmaceuticals Inc (REGN) via the Vested app. You can start investing in Regeneron Pharmaceuticals Inc (REGN) with a minimum investment of $1.
You can invest in shares of Regeneron Pharmaceuticals Inc (REGN) via Vested in three simple steps:
The 52-week high price of Regeneron Pharmaceuticals Inc (REGN) is $821.11. The 52-week low price of Regeneron Pharmaceuticals Inc (REGN) is $475.17.
The price-to-earnings (P/E) ratio of Regeneron Pharmaceuticals Inc (REGN) is 19.1212
The price-to-book (P/B) ratio of Regeneron Pharmaceuticals Inc (REGN) is 2.72
The dividend yield of Regeneron Pharmaceuticals Inc (REGN) is 0.44%
The market capitalization of Regeneron Pharmaceuticals Inc (REGN) is $83.75B
The stock symbol (or ticker) of Regeneron Pharmaceuticals Inc is REGN
Consider the share price of Regeneron Pharmaceuticals Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Regeneron Pharmaceuticals Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Regeneron Pharmaceuticals Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Regeneron Pharmaceuticals Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Regeneron Pharmaceuticals Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Regeneron Pharmaceuticals Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
